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Abstract
Background: Dyspigmentation of the oral mucosa has a multitude of aetiological causes. Retigabine, a new
antiepileptic drug, has the potential side effect of inducing a blue/purple pigmentation of the oral mucosa in
addition to the skin, lips, nails and retina of the eyes. This article presents a unique case of dyspigmentation
present in the oral mucosa of the hard palate which has previously been unreported in the dental literature.
Case presentation: A 70 year old white male presented to a secondary care oral surgery department with an
unusual asymptomatic pigmented lesion present in the hard palate of the oral cavity. The pigmentation was
remarkable for its distinct blue/purple colouration which was associated with a similar discolouration of the nail
beds of the hands. This is believed to be a side effect of the anti-epileptic medication retigabine.
Conclusion: The dental profession and wider healthcare community should be made fully aware of the potential side
effect of oral dyspigmentation associated with the novel anti-epileptic medication retigabine. Enhanced knowledge of
the causative role of retigabine in dyspigementation of the oral mucosa will allow the practitioner to make an appropriate
diagnosis. As far the authors are aware this is reaction is unreported in the dental literature and should be disseminated
to the wider oral health professional’s community.
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Background
Abnormal pigmentation of the oral mucosa can be discon-
certing to the presenting patient and examining dental
practitioner. The unexpected appearance of atypical mu-
cosal tissue challenges the dentist to formulate a practical
diagnosis, provide an explanation for the alerted mucosal
form to the patient and where appropriate facilitate man-
agement. Mucosal dyspigmentation has a diverse aetiology
varying from the nuances of physiological response
through to pathological entities including malignancy.
Retigabine was licensed in Europe for use as adjunctive
treatment for refractory partial epilepsy on 28th March
2011. Drug resistant epilepsy is currently defined as the
failure of adequate trials of 2 tolerated and appropriately
chosen and tried antiepileptic drug (AED) schedules
(whether as monotherapies or in combination) in order
to achieve sustained freedom from seizures [1]. Despite
acknowledged limitations in the epidemiological data [2]
epilepsy is regarded as the most common global disorder
of the brain with a reported prevalence of 7.3 in every
1000 people in the United Kingdom [3]. It is estimated
that one third of those diagnosed with epilepsy fail to
achieve seizure control and thus fall into the refractory
epilepsy category [4]. This in turn has a significant nega-
tive impact upon quality of life [5].
Retigabine has shown much promise in the management
of patients with refractory partial onset seizures [6, 7]. Med-
ical intervention by its very nature challenges the prescrib-
ing clinician to juxtapose the benefit to a patient’s condition
against the potential detrimental side effects of therapy. As
with all medications, retigabine carries special warnings
and precautions associated with its use. These include risk
of malaise, nausea, renal and urinary disorders, dyspepsia
and of particular interest to the dental practitioner periph-
eral oedema and dry mouth [8]. Occlular disturbance in-
cluding blurred vision in addition to dizziness and tremors
have also previously been identified [9]. Discolouration of
the retina with or without similar discolouration of the
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nails, lips and skin have been reported and some concern
exists that this effect may become permanent [10]. At
present, few reports exist in the available literature which
identify dyspigmentation of the oral mucosa as a potential
consequence of the drug retigabine [11, 12].
We present a case of altered pigmentation of the oral
mucsoa present on the hard palate in a 70 year old
gentleman receiving treatment with retigabine for more
than 2 years.
Case presentation
A 70 year old male presented to The Oral Surgery
Department at The Glasgow Dental Hospital and School
in November 2014, three weeks following an urgent re-
ferral from his general dental practitioner.
The gentleman reported having an asymptomatic purple/
blue lesion present on the roof his mouth. This was an inci-
dental finding at his most recent 3 monthly regular dental
appointment, not having been recognised prior to this.
The medical history was remarkable in that the patient
had suffered from partial onset seizures from the age of
17 years as a consequence of right sided mesial temporal
sclerosis. At the time of referral the patient was pre-
scribed a drug regime of, retigabine 300 mg three times
daily, primidone 250 mg in the morning and 125 mg in
the evening, zonisamide 200 mg in the morning and
300 mg in the evening and clobazam 20 mg at night, to
manage his partial onset seizure. The gentleman had
initiated retigabine therapy in April 2012 and it had sub-
stantially improved his seizure control. Despite reporting
falling asleep easily, he otherwise functioned well and
thus was maintained on this drug regieme. Additionally,
the patient had a diagnosis of osteoporosis, for which he
was receiving alendronic acid and calcichew. He was also
prescribed omeprazole in order to manage the dyspepsia
associated with a hiatus hernia. He has never smoked or
used tobacco products and consumes 10 units of alcohol
per week. He regularly attends the dentist and does not
wear an intra-oral prosthesis.
Extra-oral examination revealed a purple/blue discolour-
ation of the nail beds of both the left and right hands (Fig. 1)
and the lips were tinged with a bluish hue extending to the
vermillion border. No alteration in the pigmentation of the
retina of the eyes was observed on examination. No other
skin abnormalities were reported by the patient or observed
by the examining clinician.
Intra-oral soft tissue examination revealed the mucosa
of the hard palate was dyspigmented being a purple/
blue colour (Fig. 2). The colour observed was identical
to that noted in the nail beds of the hands. The discol-
ouration of the palate observed was uniform, extending
symmetrically across the mucosa from the median palat-
ine suture to the gingival margins on the palatal aspect
of the teeth. The epithelium was intact and showed no
other signs of abnormality other than the altered colour.
On further detailed questioning the gentleman reported
that he had been aware of the discolouration of the nail
beds but as they had caused him no symptoms he was un-
concerned. The patient was able to recall that this altered
colouration had developed within the previous 3 months.
The timing of the appearance of the pigment within the
nail beds is consistent with the development of the blue
pigmentation within the oral mucosa, as the patient had
received an oral examination 3 months ago where no
changes in the oral mucosa were reported by the oral
health professional.
No further special investigations were undertaken at
this stage as the appearance of the mucosa observed was
consistent with the skin pigmentation observed and cor-
responded with available reports. Temporal factors were
important to the formulation of the diagnosis as the pig-
mentation observed only became evident subsequent to
the patient beginning therapy with the drug retigabine.
Furthermore, the accepted side effect of pigmentation of
the nail beds appears to have occurred within the same
time period as the discolouration of the oral mucosa.
The notable similarity in colour of the dyspigmented
skin and oral mucosa further supported the diagnosis.
Other possible diagnoses were excluded based on clin-
ical expertise. A vascular cause was considered however,
no blanching was observed when pressure was applied
to the mucosa nor was there any increase in cellular
number or size which would clinically present as an
abnormal lump or growth.
Fig. 1 Purple/blue discolouration of the left and right nail beds of the hands
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Melanoma, typically presents as invasive or raised le-
sion with a dark-brown or bluish-black pigmentation.
The lesion observed was notably distinct from this in
both colouration and the intact nature of the mucosa.
Similarly, Kaposi’s sarcoma, a lesion synonymous with
H.I.V., was ruled out as a possible diagnosis as typical
features such as a reddish purple pigmentation and
nodular surface were absent. Furthermore, the patient
did not report having a blood borne virus nor did he dis-
play any signs of being in a high risk group for a blood
borne virus.
It is the belief of the authors that blue pigmentation
was an extension of the previously reported skin alter-
ation. Biopsy was considered however when taking all
factors into consideration surgical sampling was deemed
not to be justified. The clinical features observed were
considered to be consistent with the appearance of pig-
mented change as a consequence of retigabine’s use at
other sites reported within the medical literature and
together with the absence of confirmatory diagnostic
histopathological criteria for retigabine induced dyspig-
mentaion a clinical decision not to biopsy the mucosa
was made [11]. Other possible systemic pathological
causes were excluded on clinical grounds and recent
blood sampling showed no irregularities indicating the
need for further investigation.
The patient was reviewed six weeks following initial
examination. There were no notable changes in the pa-
tient’s symptoms or the clinical appearance of the mucosa.
A further six month review is scheduled when the clinical
appearance of the oral mucosa will be re-evaluated.
Discussion
Dyspigmentation of the oral mucosa has a varied aetiology
which must be fully considered by the diagnosing clin-
ician. Oral manifestations of systemic disease can present
as altered mucosal pigmentation including: Addison’s
disease, Cushing’s syndrome, Peutz-Jeghers syndrome [13]
and McCune Albright syndrome [14]. Addison’s disease,
an endocrine pathology of the adrenal gland results in
decreased cortisol and aldosterone production. Darkening
of the skin, much like the appearance of a sun tan is one
of the most notable features. Other symptoms include
malaise, muscle weakness, unintentional weight loss and
increased thirst [15]. Further investigation for diagnostic
purposes would include measuring blood cortisol levels
and if sufficiently low an ACTH simulation test may be
indicated. The person with correctly diagnosed Addison’s
disease would have no increase in the levels of hormone
secreted following administration of the ACTH.
Cushing’s syndrome, another endocrine disease, results
in an increased secretion of ACTH from the pituitary
gland as a result of long term steroid use (iatrogenic) or
due to disease of the gland itself (endogenous). Symp-
toms include weight gain with associated fatty deposits
of the face resulting in characteristic “cushinoid features”
and the appearance of red/purplish markings on the
proximal aspects of the body. Special investigations
attempt to measure the level of cortisol using a urine
test, salivary sampling or a steroid suppression test [16].
However, variation in the pigmentation of the oral
mucosa can be entirely benign, exemplified in the oral
mucosa of those darker skinned racial groups as a result
of entirely normal physiological melanin production.
The variation in pigmentation is most pronounced in
the anterior aspects of the mouth and tends to increase
in both intensity and surface area with increasing age
[17]. Other melanocytic lesions tend to present in a focal
region of the mouth and include melanocytic macule,
melanocytic naevus, melancanthoma, smoking induced
melanosis and melanoma [18].
A discolouration of the oral mucosa can result from
the deposition of exogenous materials. Common to the
dental practitioner is the amalgam tattoo which presents
as a localised grey region in the mucosa as a result of
amalgam fragments being introduced into the tissues
following tooth restoration or extraction [19]. Historic-
ally, other heavy metals including bismuth and lead re-
sulted in a linear patterned blue/black pigmentation
which follows the gingival contour as precipitates are
exuded in gingival crevicular fluid as a consequence of
occupational exposure or medical therapies [20].
A growing number of reports of oral post inflamma-
tory pigmentation are appearing in the literature. Fol-
lowing chronic inflammatory states present in the oral
tissues, such as that induced by lichenoid reactions and
lichen planus, excess deposits of melanin develop in the
epithelial basal layer and surrounding connective tissue
of the oral mucosa [21].
A multitude of medications are cited as inducing colour
change within the tissues of the mouth. The antimalarial
Fig. 2 Purple/blue dyspigmentation of the mucosa of the hard palate
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drugs, oral contraceptives and cytotoxic agents all upregu-
late melanin production resulting in oral pigmentation
[13]. The tetracyclines, in particular minocycline, may also
induce a similar change. However, this is due to staining
of the underlying hard tissues not as a consequence of
increased melanin present in the mucosa [22].
The medication retigabine, a therapy used for the
management of drug-resistant epilepsy, is the first avail-
able neuronal potassium channel opening drug [23]. It
acts to improve the stability of neurones, subsequently
preventing seizures [24]. The results obtained with reti-
gabine in phase III regulatory trials have been positive in
the clinical management of refractory epilepsy [6, 7]. It
is unfortunate that the significant side effects associated
with retigabine have resulted in the European Medicines
Agency (EMA), to recommend retigabine as a last resort
therapy [25]. This recommendation is primarily as a
result of the pigmentation of the skin, nails, lips and eye
tissues which can develop following its use.
The findings in this case report provide further evidence
that retigabine induces a blue purple pigment change to
the skin and mucosa including the oromucosal tissue of
the hard palate. There is only one previous publication,
which the authors are aware of that has noted changes in
the oral mucosal tissue, [11]. It is important that the den-
tal profession is aware of this new drug reaction in order
to provide a diagnosis and be able to inform patients.
The mechanism in which this pigmentation is induced
is as yet unknown. Recent studies in rats have implicated
pigmented dimerization products of retigabine in produ-
cing the discolouration [26]. The histopathological fea-
tures reported in a biopsy sample of dyspigemtend
mucosa of the hard palate by Shkolnik, showed normal
epithelium without any melanin pigmentation [11]. How-
ever, melanin was evident in the submucosal macrophages
and extracellular matrix. Further testing to isolate the drug
in the mucosal sample using nuclear magnetic resonance
and mass spectrometry were unable to identify the pres-
ence of retigabine directly within the specimen. The group
propose a “Tyndall effect” to explain the appearance of
the pigmented mucosa. The blue clinical appearance of
melanin is explained as a result of short wavelength blue
light being scattered the most when compared to other
wavelengths.
No active treatment is required to manage this oral
pigmentation. However, liason with medical colleagues
should facilitate an opportunity for the physician and
patient to re-evaluate continuation of therapy to manage
partial-onset seizures.
Patients who exhibit extra-oral features of this reaction
should be encouraged to avoid and protect the skin from
sunlight as this may well precipitate the reaction. It is
unclear at present if the pigmentation will resolve fol-
lowing cessation of the medication. Shkolnik’s reported
case did show improvement in the pigmentation following
discontinuation of retigabine. Although, the F.D.A. report
suggests that the pigmentation has the potential to be per-
manent [10], whilst Scholnik's report suggested that the
problem may reversible on stopping the drug [11]. In this
presented case it is possible but unlikely that the other
medications taken by the patient have a role in initiating
or perpetuating the dyspigmentation present in the oral
mucosa. It is clear further research is required to increase
the understanding of such reactions and their long term
outcomes.
Conclusions
The clinical presentation of abnormal oral mucosal pig-
mentation is a challenge for the examining clinician to
accurately diagnose. The dental practitioner should have
a thorough understanding of the causes of oral mucosal
lesions and causes of pigmentation. They must be able
to facilitate diagnosis and instigate referral to specialist
services where necessary. The AED, retigabine is a new
medication which the practicing dental professional
should be aware of as it can result in dyspigmentation of
the mucosa of the hard palate in addition to the nails,
skin and retina of the eyes.
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